An observational study in NIRS, Tissue Oxygenation and Microvascular Perfusion, sponsored by Heinrich-Heine University, Duesseldorf. Recruiting at 1 site in Germany. Open to participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Heinrich-Heine University, Duesseldorf · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Ischemia with a site in Germany — 6 open to participants now, 9 under way, 1 of them phase 3. Ischemia · Germany.
Among the 46 studies in Ischemia with a site in Germany, this one is the 14th largest by planned enrollment of the 15 observational ones that give a count, is one of 2 that started in 2026, is one of 15 observational ones, and was the 46th registered.
545 studies on the registry are indexed under Ischemia; 71 are open to participants now.
Browse Ischemia studies →6 of the 46 studies in Ischemia with a site in Germany are open now. Recruiting first, the newest first:
Penumbra Inc. · Sites in Germany, United States, Australia and 4 more countries
Ages 18+
University Hospital Augsburg · Sites in Germany
Ages 18+
University Hospital, Essen · Sites in Germany
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Germany, Australia, Austria and 5 more countries
Ages 6 mo–17 yrs
iVascular S.L.U. · Sites in Germany, France
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 44 Ischemia studies recruiting now, 34 (77%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.
This study: 20 Years to 40 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 11 · Phase 4 4
First in 1998; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 176 across 166 observational studies indexed under Ischemia.
Median enrollment 100 across the 31 interventional studies, 119 across the 15 observational. Of the 30 that completed or were terminated, 7 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 46 have an industry lead sponsor. The 10 most frequent:
Heinrich-Heine University, Duesseldorf is the lead sponsor of 180 studies on the registry; 54 are open to participants now.
Heinrich-Heine University, Duesseldorf has 1 study filed under Ischemia — fewer than ten, so there is no comparison to draw.
3 of the studies in Ischemia with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07357285iVascular S.L.U.Safety and Efficacy Evaluation of the iNstroke 4F Thromboaspiration Catheter in Patients With Acute Ischaemic Stroke Due to Primary Distal Medium Vessel Occlusions (DMVO) | 2026-11 |
| NCT07854431Heinrich-Heine University, DuesseldorfCHECK-NIRS2D-Study | 2027-03-01 |
| NCT07376447iVascular S.L.U.Evaluation of iNstroke Aspiration Catheters for Thrombectomy: a Multi-center Prospective Study | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 46 studies in Ischemia with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study investigates how external, physiological, and behavioral factors influence the measurement of regional tissue oxygenation using two-dimensional near-infrared spectroscopy (NIRS) imaging in healthy volunteers. It aims to improve the standardization and reliability of this non-invasive method for assessing microvascular perfusion and tissue oxygenation.
The study also examines the effects of temporary vascular occlusion, ambient temperature, physical activity, caffeine consumption, and nicotine consumption on NIRS-based tissue oxygenation measurements. The findings are intended to establish a standardized measurement protocol for future clinical research and the assessment of microvascular perfusion in critically ill patients.
The study is a prospective, monocentric, controlled experimental study in healthy volunteers. It examines how external conditions, physiological states, and everyday behaviors influence measurements obtained with two-dimensional near-infrared spectroscopy (2D-NIRS). The imaging method is intended to assess local tissue oxygenation and microvascular perfusion non-invasively.
Detailed study description
General purpose
The CHECK-NIRS2D study is a prospective, monocentric, controlled experimental study conducted at the University Hospital Düsseldorf. It investigates how external conditions, physiological states, and behavioral factors influence measurements of local tissue oxygenation obtained using two-dimensional near-infrared spectroscopy (2D-NIRS).
The study uses the SnapshotNIR camera system (KD203, Kent Imaging Inc., Calgary, Canada). This non-invasive method produces spatially resolved images of tissue oxygenation, allowing the investigators to examine not only the overall oxygenation of a tissue region but also possible differences in perfusion between individual areas.
The study is intended as physiological and methodological research. It does not evaluate the therapeutic efficacy or safety of the device and does not provide a direct medical benefit to participants. Its longer-term objective is to develop a standardized protocol for future studies involving patients with acute or chronic diseases, particularly in emergency and intensive-care medicine.
Participants
The study plans to include healthy adults:
Participants who regularly use medication affecting the cardiovascular system or blood coagulation, as well as pregnant or breastfeeding participants, are excluded.
Five substudies, designated A-E, are planned. Approximately 20 participants per experimental group are intended. Participants may take part in more than one substudy, but this is voluntary. The order of experimental protocols is randomized, and a recovery period of at least 60 minutes is planned between measurements of the same extremity, except where the caffeine- and nicotine-specific protocols require a different arrangement.
The examinations generally take place with the participant sitting upright. The arm to be examined is positioned beside the body, with the palm facing upwards and the elbow approximately at the level of the lower end of the sternum.
The following measurements are generally performed:
Depending on the substudy, this is performed at baseline and at the end of the experiment or repeatedly during control measurements.
During the standard VOT protocols, heart rate, blood pressure, SpO₂, and pain are generally recorded at one-minute intervals. NIRS imaging and capillary reperfusion measurements are performed at shorter intervals during ischemia and early reperfusion, including every 30 seconds during ischemia and during the first five minutes after reperfusion begins.
The protocol includes:
healthy volunteers
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
predefined measurements
Standardized 2D-NIRS imaging at rest under predefined reference conditions, including the protocol-defined VOT.
microvascular tissue oxygenation
StO₂, expressed as a percentage
Time frame: within 20 Minutes of ischemia/reprefusion protocol measurement
Retinal funduscopy parameters
measured by NIRS
Time frame: within 20 Minutes of ischemia/reprefusion protocol measurement
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Mar 2027, 7 months after the start.
Of 48 non-industry observational studies under Ischemia, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 24. This study's planned 7 months is below that.
Counting every sponsor, half of 70 studies reached it within 35 months; a quarter within 22 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Heinrich-Heine University, Duesseldorf →